Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2017

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands):

		Three Months Ended September 30,				Nine Months Ended September 30,
Agreement	Deliverable	2017		2016		2017		2016
Japan	License	$	445	$	3,041	$	936	$	3,159
	Milestones		—		—		—		10,000
	Total license and milestone revenue		445	$	3,041	$	936	$	13,159
	Collaboration services revenue*		22	$	144	$	46	$	151

When and if available compounds, manufacturing — clinical supplies and committee services have each been identified as separate units of accounting with standalone value and amounts allocable to these elements have been recognized and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through September 30, 2017		Deferred Revenue at September 30, 2017		Total Consideration Through September 30, 2017
License	$	46,646	$	—	$	46,646
When and if available compounds		24		24		48
Manufacturing--clinical supplies		2,164		—		2,164
Committee services		21		—		21
Total license and collaboration services revenue	$	48,855	$	24	$	48,879

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Three Months Ended September 30,				Nine Months Ended September 30,
Agreement	Deliverable	2017		2016		2017		2016
Europe	License	$	3,680	$	1,330	$	10,716	$	7,568
	Milestones		—		—		—		—
	Total license and milestone revenue		3,680		1,330		10,716		7,568
	Collaboration services revenue*	$	423	$	292	$	1,184	$	963

When and if available compounds, manufacturing — clinical supplies, development services — in progress at the time of signing of the agreement, and committee services have each been identified as a separate unit of accounting with standalone value and amounts allocable to these units have been recognized in revenue as services are performed and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through September 30, 2017		Deferred Revenue at September 30, 2017		Total Consideration Through September 30, 2017
License	$	422,988	$	—	$	422,988
When and if available compounds		434		394		828
Manufacturing--clinical supplies		10,132		—		10,132
Development services--in progress		33,892		—		33,892
Committee services		293		—		293
Total license and collaboration services revenue	$	467,739	$	394	$	468,133

U.S./RoW [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

		Three Months Ended September 30,				Nine Months Ended September 30,
Agreement	Deliverable	2017		2016		2017		2016
U.S. / RoW and China	License	$	15,872	$	16,496	$	49,278	$	93,075
	Milestones		—		—		—		—
	Total license and milestone revenue		15,872		16,496		49,278		93,075
	Collaboration services revenue*		6,830		8,784		20,997		32,723
	China single unit of accounting**	$	—	$	—	$	—	$	—

Co-development, information sharing, and committee services have been combined into a single unit of accounting because the requirements to share information and serve on committees are useful only in combination with the development services, and because all three items are delivered over the same period while manufacturing — clinical supplies has been identified as a separate unit of accounting with standalone value and amounts allocable to this unit of accounting have been recognized and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

All revenues attributable to the China unit of accounting are deferred until all deliverables are met. The China license and collaboration services elements have been combined into a single unit of accounting and consideration allocable to this unit is being deferred due to FibroGen’s retention of manufacturing rights and lack of standalone value.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the U.S./RoW Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through September 30, 2017		Deferred Revenue at September 30, 2017		Total Consideration Through September 30, 2017
License	$	451,974	$	—	$	451,974
Co-development, information sharing & committee services		111,693		25,723		137,416
Manufacturing--clinical supplies		436		34		470
China-single unit of accounting		—		92,643		92,643
Total license and collaboration services revenue	$	564,103	$	118,400	$	682,503